Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

  • Poster presentation
  • Open access
  • Published:

Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors


Host defense peptides (HDPs) are naturally occurring molecules found in most eukaryotic species, in which they play a significant role in the first line of defense against pathogens. Several HDPs have shown to possess anticancer activity. Structure-anti-cancer activity relationship studies on the HDP bovine lactoferricin has resulted in the design of a short oncolytic 9-mer peptide, LTX-315. Mode of action studies indicate that LTX-315 induces release of tumour antigens and potent DAMPS by distortion of intracellular organelles in cancer cells. Animal studies have demonstrated that intratumoural (i.t.) treatment of several different types of syngeneic murine tumours with LTX-315 resulted in complete tumor regression and tumor specific immune responses. In the present study, we examined the potential synergistic effects of using LTX-315 in combination with anti-PD1 or anti-CTLA4 blockade.


C57BL/6 mice with MCA205 sarcomas were first treated i.p. with either anti-PD1 Ab or anti-CTLA4 Ab followed by intra-tumoural administration of LTX-315.


Intratumoural (i.t.) administration of LTX-315 resulted in a synergistic antitumour effect when combined with i.p. administration of anti-PD1 or anti-CTLA4 compared to the effect of either the immune checkpoint inhibitors or LTX-315 alone. A synergistic effect was also achieved against distant non-treated lesions with local administration of anti-CTLA4 Ab (s.c.) and LTX-315 (i.t.) in combination.


Our results demonstrate that LTX-315 in combination with anti-CTLA4 or anti-PD1 results in a synergistic antitumour effect in vivo. Thus, a combination therapy with the oncolytic peptide LTX-315 that mounts specific T cell responses against released tumour antigens and immune checkpoint inhibitors that can augment the tumour specific T cell responses represent a promising combination strategy in future cancer therapy. One Phase I study with LTX-315 is completed and a 2nd is ongoing. Combination studies together with immune checkpoint inhibitors are planned.

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rekdal, Ö., Yamazaki, T., Sveinbjornsson, B. et al. Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors. j. immunotherapy cancer 3 (Suppl 2), P375 (2015).

Download citation

  • Published:

  • DOI: